Fig. 3.

Model-based simulation of MMF concentration–time profiles (a) and MMF C_{max0–12h,ss} (b) with meal fat content in healthy participants and patients with MS following administration of DRF 462 mg BID. Reference: in the simulations for a, participants had body weight of 78 kg and eGFR of 111.9 mL/min. Reference: in the simulations for b, individual population-predicted–derived concentration–time profiles were generated for participants with body weight of 78 kg and eGFR of 111.9 mL/min. Simulation: four virtual healthy participants (one fasted and on per meal fat content category: low, medium, high) and one virtual patient (unknown meal fat content); N = 1000 per participant. Dose: 462 mg DRF BID for 7 days. BID twice daily, C_max0-12h,ss, steady state maximum concentration for the 0–12-h dosing interval following a morning dose, DRF diroximel fumarate, eGFR estimated glomerular filtration rate, HV healthy volunteer, MMF monomethyl fumarate, MS multiple sclerosis